Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Biliary Tract Neoplasms × folfirinox × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 17 Neoplasms 4 Urachal cancer 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Pancreatic Cancer Metastatic 1 Neoplasm Metastasis 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Hepatocellular 1 Borderline Resectable Pancreatic Cancer 1 Biliary Tract Neoplasms 1 Adenocarcinoma 1

Interventions

Gemcitabine 35 Cisplatin 27 Oxaliplatin 19 Capecitabine 16 Fluorouracil 13 Leucovorin 12 Irinotecan 10 pembrolizumab 9 lenvatinib 8 durvalumab 7 Bevacizumab 7 S 1 (combination) 6 apatinib 5 Nivolumab 5 tremelimumab 4 Trastuzumab 4 Injections 4 Docetaxel 4 trametinib 3 titanium silicide 3 irinotecan sucrosofate 3 envafolimab 3 camrelizumab 3 atezolizumab 3 Drug Therapy 3 toripalimab 2 surufatinib 2 pertuzumab 2 gemcitabine-oxaliplatin regimen 2 brigimadlin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03291899 2024-01-17

FBI-TRAC

King Faisal Specialist Hospital & Research Center

Phase 2 Terminated

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡